What is the 13F Pro Quality Score for CYPH?

13F Pro ranks CYPHERPUNK TECHNOLOGIES INC. (CYPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYPH's current score at https://13fpro.ai/research/CYPH (free sign-up required for the full ranking).

Where does 13F Pro source CYPH data?

All CYPHERPUNK TECHNOLOGIES INC. fundamentals and ownership data come directly from SEC EDGAR. CYPHERPUNK TECHNOLOGIES INC. files with the SEC under CIK 1509745. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYPH in?

CYPHERPUNK TECHNOLOGIES INC. (CYPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYPH research updated on 13F Pro?

CYPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CYPHERPUNK TECHNOLOGIES INC.(CYPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1509745 CYPH stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CYPH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CYPHERPUNK TECHNOLOGIES INC. (CYPH), a Healthcare sector company. CYPH is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), CYPHERPUNK TECHNOLOGIES INC. reports net income of $-77.2M, free cash flow of $-3.4M. Top institutional holders of CYPH by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CYPH trades on the Nasdaq exchange and files with the SEC under CIK 1509745. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CYPHERPUNK TECHNOLOGIES INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-77.2M

Free Cash Flow

Q1 2026

$-3.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $1.5MFY23 —FY24 —FY25 —

Net Income

+107.4% YoY

$5.0MFY 2025

FY21 $-40.6MFY23 $-81.0MFY24 $-67.6MFY25 $5.0M

Operating Income

+41.4% YoY

$-41.1MFY 2025

FY21 $-41.4MFY23 $-87.0MFY24 $-70.1MFY25 $-41.1M

EPS (Diluted)

+107.7% YoY

$0.07FY 2025

FY21 $-0.47FY23 $-1.99FY24 $-0.91FY25 $0.07

Total Assets

+232.2% YoY

$163.2MFY 2025

FY21 $117.9MFY23 $72.8MFY24 $49.1MFY25 $163.2M

Op. Cash Flow

+27.2% YoY

$-43.9MFY 2025

FY21 $-35.2MFY23 $-43.8MFY24 $-60.3MFY25 $-43.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	—	—	—	$1.5M +0.0%	$1.5M	—
Net Income	$5.0M +107.4%	$-67.6M +16.6%	$-81.0M -99.6%	$-40.6M -47.5%	$-27.5M +16.4%	$-32.9M
Operating Income	$-41.1M +41.4%	$-70.1M +19.5%	$-87.0M -110.1%	$-41.4M -45.2%	$-28.5M +14.7%	$-33.5M
EPS (Diluted)	$0.07 +107.7%	$-0.91 +54.5%	$-1.99 -323.4%	$-0.47 +25.4%	$-0.63 +57.1%	$-1.47
Total Assets	$163.2M +232.2%	$49.1M -32.5%	$72.8M -38.2%	$117.9M +116.9%	$54.4M +630.0%	$7.4M
Operating Cash Flow	$-43.9M +27.2%	$-60.3M -37.8%	$-43.8M -24.5%	$-35.2M -35.4%	$-26.0M +3.5%	$-26.9M

AI Insight: CYPH Financial Trends

Profitability inflection in Q4 2025 reversed sharply in Q1 2026, with net loss of $77M wiping out prior-quarter gains despite operating losses stabilizing.

• Net income swung from $40M profit in Q4 2025 to $77M loss in Q1 2026, largest quarterly loss in dataset.

• Operating cash burn improved from $14M–$16M range in 2024–2025 to $3M–$7M in latest two quarters.

• Equity collapsed from $66M in Q2 2024 to $3M in Q3 2025, recovered to $84M in Q4 2025, then halved to $84M in Q1 2026.

⚠ Q4 2025 $40M net income spike lacks revenue data; Q1 2026 reversal suggests one-time item or accounting adjustment, not sustainable ops.

⚠ Equity volatility (ranging $3M–$154M) and persistent operating losses indicate balance-sheet fragility despite recent equity injection.

AI Insight: CYPH Ratio Trends

CYPH swung from deeply negative returns in 2024 to near-breakeven profitability in Q4 2025, but latest ROIC deteriorated, signaling fragile turnaround.

• ROE collapsed from -176.1% in Q4 2024 to +104.8% in Q4 2025, suggesting sharply improved net income or reduced equity base.

• TTM ROA improved to -65.1% from Q4 2024's trough, indicating operational recovery, though still deeply negative.

• ROIC deteriorated to -22.8% in Q1 2026 from -13.3% in Q4 2025—first sequential decline, reversing momentum.

⚠ Stark data gaps (Q1–Q3 2025 blank) prevent granular trend confirmation; Q4 2025 spike may reflect one-time items.

⚠ Company remains unprofitable on TTM basis and ROIC; Q4 2025 rebound not yet sustained into Q1 2026.

Get alerted when CYPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CYPHERPUNK TECHNOLOGIES INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYPH

BlackRock, Inc.
$1.9M2,342,174 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.4M1,818,414 sh
RENAISSANCE TECHNOLOGIES LLC
$576.2K725,120 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$457.8K579,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$453.9K571,068 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$296.3K375,100 sh
Arete Wealth Advisors, LLC
$294.7K12,488 sh
VANGUARD FIDUCIARY TRUST CO
$236.2K297,086 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$208.9K262,953 sh
CITADEL ADVISORS LLC
$144.1K181,300 sh

Fund	Value	Shares
BlackRock, Inc.	$1.9M	2,342,174
VANGUARD CAPITAL MANAGEMENT LLC	$1.4M	1,818,414
RENAISSANCE TECHNOLOGIES LLC	$576.2K	725,120
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$457.8K	579,500
GEODE CAPITAL MANAGEMENT, LLC	$453.9K	571,068
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$296.3K	375,100
Arete Wealth Advisors, LLC	$294.7K	12,488
VANGUARD FIDUCIARY TRUST CO	$236.2K	297,086
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$208.9K	262,953
CITADEL ADVISORS LLC	$144.1K	181,300

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYPH on your watchlist

Track score changes the day CYPHERPUNK TECHNOLOGIES INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYPH a good stock to buy?

13F Pro's AI-powered analysis of CYPHERPUNK TECHNOLOGIES INC. (CYPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYPH are available on the CYPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CYPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CYPHERPUNK TECHNOLOGIES INC.'s investment landscape.